Skip to main content
GameRevenueData

Publisher

Games Published by USANIK STD: Revenue & Sales Estimates

Revenue estimates for the 8 Steam games published by USANIK STD, ranked by estimated net revenue. Available estimated lifetime net (USD): $14.1K.

Catalog Est. Lifetime Net (USD)

$14.1K

Estimates for 3 of 8 tracked games

Tracked games

8

Top Earner

Active Neurons - Puzzle game

$9.9K

Coverage: 8 tracked titles; 3 with net estimates; 5 without. 3 have dedicated profiles. Missing estimates are excluded from the aggregate, not treated as known zero revenue.

Role: Publisher. These are lifetime estimates for games credited to USANIK STD; they are not company earnings, profit, or contractual receipts. Credits may omit co-development or historical publishing arrangements. Developer and publisher identities are not merged by matching names.

Recorded release dates: 2017-03-24–2024-06-12 (may include announced dates).

Largest title accounts for 70.3% of available estimated net revenue. Coverage gaps can change this share.

Showing 1–8 of the top 8 displayed entries, from 8 tracked titles. Figures include only available estimates. Search the full catalog .

Rows 1–8 Β· Page 1 of 1

# Game Est. lifetime net (USD) Positive reviews (raw) Release
1 Active Neurons - Puzzle game $9.9K 94%Positive (68) Oct 15, 2019
2 Active Neurons 2 $2.4K 95%Positive (21) Apr 15, 2020
3 Fusion Paradox πŸ”« $1.8K 82%Positive (11) Apr 10, 2023
4 Grass Cutter - Mutated Lawns β€” 88%Positive (334) Mar 24, 2017
5 Nice Jumper β€” 82%Positive (339) Aug 9, 2019
6 Active Neurons - Wonders Of The World β€” 95%Positive (191) Oct 13, 2020
7 Knowledge Keeper β€” 100%Positive (6) Jun 12, 2024
8 Galactic Exile β€” (0) β€”

Get real-time dashboards, historical trends, and AI-powered analysis

Explore on PlayRev(opens in new tab)

Revenue and sales estimates are based on the Boxleiter method using publicly available data including Steam review counts, pricing history, and statistical modeling. Actual revenue may differ significantly. These figures are provided for informational purposes only and should not be used for financial decisions. Read the full methodology.